ESTRO 2024 - Abstract Book

S1450

Clinical - Head & neck

ESTRO 2024

chemotherapy in Rambam Health Care Campus (RHCC) due to HNC with radiation doses between 60 Grays to 70 Grays, ECOG performance status 1-3, were instructed to use B-Cure Laser PBM devices (Erika B-Cure Laser Ltd, Haifa, Israel) in addition to standard of care. Patients self-applied the treatment at home (wavelength 808 nm, power 250 mW/cm2, 1 minute per spot, 3-6 spots, Beam area 4.5 cm2) twice daily for 11 weeks on anatomical locations predefined by a radiation oncologist and an oral medicine specialists based on the radiation field. The primary outcome was the proportion of patients that performed at least 50% of expected daily treatments during the radiotherapy period. Secondary outcomes included OM and RD; were graded using Common Terminology Criteria for Adverse Events (CTCAE) v5.0 at baseline, three weeks after RT initiation, at the end of RT treatment, and one month later. On each evaluation time point; compliance, ease and comfort of use on a visual analog scale (VAS), and Functional Assessment of Cancer Therapy Head & Neck Cancer Symptom Index (FHNSI) were asked to be filled by the patients. 20 patients were included with a median age of 76 (43-80), 14 males and 6 females. 19 had squamous cell carcinoma; the primary cancer site was the oral cavity in 5 patients, the nasopharynx in 4 patients, the oropharynx in 4 patients, the larynx in 4 patients, and the skin in 3 patients. 11 had concurrent chemotherapy, and 5 had neoadjuvant and concurrent chemotherapy. Two patients were screen failures, 3 patient withdrew consent, and two patients' information were missing due to low compliance. 15 patients were evaluated. The proportion of patients that adhered to the protocol was 60%, with all participants (100%) reporting VAS=10 comfort and ease of use of the device. At the end of radiation treatment, 4 of 15 patients developed severe dermatitis (1 with grade 4) and 7 of 15 patients developed severe oral mucositis (6 with grade 3). Severe OM or DM was not observed 4 weeks after the end of radiation, patient reported FHNSI score was not different compared to baseline. No unexpected side effects or AEs were reported. Results:

Conclusion:

self-applied BPM is easy, comfortable, and feasible for head and neck patients; clinical outcomes need to be investigated in larger placebo-controlled randomized studies.

Keywords: photobiomodulation, HeadnNeck, toxicity prevention

References:

1. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, Bowen J, Gibson R, Saunders DP, Zadik Y, Ariyawardana A, Correa ME, Ranna V, Bossi P; Mucositis Guidelines Leadership Group of the Multinational Association of Supportive Care in Cancer and International Society of Oral Oncology (MASCC/ISOO). MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020 Oct 1;126(19):4423-4431. doi: 10.1002/cncr.33100. Epub 2020 Jul 28. Erratum in: Cancer. 2021 Oct 1;127(19):3700. PMID: 32786044; PMCID: PMC7540329.